Aurinia Sustainability Profile
Aurinia Pharmaceuticals Inc., commonly referred to as Aurinia, is a biopharmaceutical company headquartered in Canada. Founded in 2013, Aurinia focuses on developing innovative therapies for autoimmune diseases, with a particular emphasis on lupus nephritis. The company has made significant strides in the industry, notably with the launch of its flagship product, LUPKYNIS™ (voclosporin), which offers a unique mechanism of action that enhances treatment options for patients. With a strong presence in North America and expanding operations in Europe, Aurinia has established itself as a leader in the autoimmune disease sector. The company’s commitment to research and development, coupled with its strategic partnerships, has positioned it favourably in the market, earning recognition for its contributions to patient care and treatment advancements.
DitchCarbon Score
How does Aurinia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aurinia's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aurinia's reported carbon emissions
In 2023, Aurinia Pharmaceuticals Inc. reported total carbon emissions of approximately 218,430 kg CO2e. This figure represents their global emissions for the year, with no specific breakdown provided for Scope 1 or Scope 3 emissions. In 2022, the company disclosed Scope 2 emissions of about 198,740 kg CO2e, indicating a focus on indirect emissions associated with energy consumption. Aurinia has not set specific reduction targets or initiatives, nor do they participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of defined reduction strategies suggests a need for further commitment to climate action within the pharmaceutical industry context. The emissions data is not cascaded from any parent organisation, indicating that Aurinia Pharmaceuticals Inc. is independently reporting its carbon footprint. As the company continues to grow, it may benefit from establishing clear climate commitments and reduction targets to align with industry standards and expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | - | - |
| Scope 2 | 198,740 | - |
| Scope 3 | - | - |
How Carbon Intensive is Aurinia's Industry?
How Carbon Intensive is Aurinia's Location?
Aurinia's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aurinia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
